STOCKHOLM, Sweden–(EMWNews)–Regulatory News:

Vitrolife launched a new needle for the collection of human oocytes at

ESHRE, the largest congress of the year within IVF. “The

needle combines the good properties of our previous needles with a new

way of designing the front part and tip, so that the patient will

experience less discomfort. We are extremely happy about the positive

response and attention that this needle received at the congress,”

says Nils Sellbom, Sales Director at Vitrolife.

At the annual European reproduction congress ESHRE in the beginning of

July a new needle, Swemed Sense™, was

launched. The needle is designed with a thinner front part and tip so as

to minimize tissue damage, bleeding and pain. As the body of the needle

has a larger diameter, the ability to collect the oocytes from the woman

is not reduced, however. The procedure is just as fast as when a thicker

needle is used. A patent application has been submitted for Swemed Sense™.

It is estimated that the market for needles used in follicle aspiration

to collect oocytes for IVF amounts to approximately 50 million Euros.

July 14, 2008 Kungsbacka, Sweden

Magnus Nilsson CEO

Vitrolife is a global biotechnology/medical device Group that works with

developing, manufacturing and selling advanced products and systems for

the preparation, cultivation and storage of human cells, tissue and

organs. The company has business activities within three product areas:

Fertility, Transplantation and Stem Cell Cultivation. The Fertility

product area works with nutrient solutions (media) and advanced

consumable instruments such as needles and pipettes, for the treatment

of human infertility. The Transplantation product area works with

solutions and systems to maintain tissue in optimal condition outside

the body for the required time while waiting for transplantation. The

Stem Cell Cultivation product area works with media and instruments to

enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company’s

products are sold in more than 80 markets. The head office is in

Kungsbacka, Sweden, and there are subsidiaries in Sweden, USA, Australia

and Italy. The Vitrolife share is listed on the OMX Nordic Exchange

Stockholm’s Nordic Small Cap list.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37

Kungsbacka, Sweden. Corporate identity number 556354-3452.

Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [email protected].

Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When

in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://newsroom.cision.com

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions